Theralase Technologies Inc. (
TSX: V.TLT,
OTC:TLTFF,
Forum) on Friday said its latest research has been accepted for peer reviewed publication. It demonstrates that a new class of anti-cancer Photo Dynamic Compounds (PDCs) based on the metal Osmium may be very effective in the destruction of cancer.
Theralase is a biotech company focused on the commercialization of medical lasers to eliminate pain and the development of PDCs to destroy cancer.
More information can be found
here.
Theralase was in the news recently when it announced that
its revenue jumped 14% in the third quarter of 2016. The company also said it has been very successful in executing on strategic objectives. They include securing U.S. Food and Drug Administration clearance for its next generation TLC-2000 Therapeutic Medical Laser System.
Full Disclosure: Theralase Technologies Inc. is a paid client of Stockhouse Publishing.